189 related articles for article (PubMed ID: 16808980)
1. Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
Cham BE; Vickery K; Tohidi-Esfahani R; Cossart Y
J Virol Methods; 2006 Oct; 137(1):160-3. PubMed ID: 16808980
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
5. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
7. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
9. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
10. Validation of biocides against duck hepatitis B virus as a surrogate virus for human hepatitis B virus.
Sauerbrei A; Schacke M; Glück B; Egerer R; Wutzler P
J Hosp Infect; 2006 Dec; 64(4):358-65. PubMed ID: 17011665
[TBL] [Abstract][Full Text] [Related]
11. Cellular immune response of ducks to duck hepatitis B virus infection.
Vickery K; Cossart Y; Dixon R
J Med Virol; 1999 May; 58(1):19-25. PubMed ID: 10223541
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of specific immune responses to duck hepatitis B virus in infected, immune, and uninfected ducks].
Tang N; Huang A; Guo S; Qi Z; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):166-8. PubMed ID: 11412394
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
Triyatni M; Jilbert AR; Qiao M; Miller DS; Burrell CJ
J Virol; 1998 Jan; 72(1):84-94. PubMed ID: 9420203
[TBL] [Abstract][Full Text] [Related]
15. Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning.
Chassot S; Lambert V; Kay A; Godinot C; Trepo C; Cova L
Virology; 1994 Apr; 200(1):72-8. PubMed ID: 7510440
[TBL] [Abstract][Full Text] [Related]
16. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica.
Han YQ; Huang ZM; Yang XB; Liu HZ; Wu GX
J Ethnopharmacol; 2008 Jun; 118(1):148-53. PubMed ID: 18495393
[TBL] [Abstract][Full Text] [Related]
18. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
19. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
[TBL] [Abstract][Full Text] [Related]
20. Cloning, expression and purification of duck hepatitis B virus (DHBV) core protein and its use in the development of an indirect ELISA for serologic detection of DHBV infection.
Liu Q; Jia R; Wang M; Huang J; Zhu D; Chen S; Yin Z; Wang Y; Chen X; Cheng A
Arch Virol; 2014 May; 159(5):897-904. PubMed ID: 24158348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]